This study aimed to systematically review and meta-analyze the value of pretransplant FDG-PET in predicting outcome after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma. MEDLINE was systematically searched; included studies were methodologically assessed and metaanalyzed, when possible. Overall methodological quality of included studies (n = 11) was poor, with moderate risk of bias in the domains of study participation (n = 7) and prognostic factor measurement (n = 7), and high risk of bias in the domains of outcome measurement (n = 10), and study confounding (n = 11). In all aggressive non-Hodgkin lymphomas, pooled sensitivity and specificity were 54.0% and 73.1% in predicting treatment failure, and 54.5% and 68.7% in predicting death. Because of interstudy heterogeneity, additional subgroup analyses were performed. In newly diagnosed aggressive non-Hodgkin lymphoma, pooled sensitivity and specificity were 20.0% and 70.0% in predicting treatment failure, and 8.3% % and 30.5% in predicting death. In refractory/relapsed aggressive non-Hodgkin lymphoma, pooled sensitivity and specificity were 68.1% and 72.1% in predicting treatment failure, and 77.3% and 69.6% in predicting death. At present, pretransplant FDG-PET cannot be recommended in aggressive non-Hodgkin lymphoma, because available studies suffer from major methodological flaws, and reported prognostic estimates are low (i.e., poor in newly diagnosed and moderate in refractory/relapsed aggressive nonHodgkin lymphoma).
Non-Hodgkin lymphoma accounts for approximately 4-5% of all newly diagnosed cancers and is responsible for about 3-4% of all cancer-related deaths in the Western world (1) . Aggressive non-Hodgkin lymphoma accounts for approximately 50% of cases, with diffuse large B-cell lymphoma (DLBCL) being the most common subtype (2) . Despite improved therapies for aggressive non-Hodgkin lymphoma, the outcome of patients with refractory or relapsed B-or Tcell non-Hodgkin lymphoma after primary therapy remains poor (3, 4) . The standard of care in this setting is salvage chemotherapy followed by high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) (3, 5, 6) . However, this therapy is only suitable for fit, younger patients who demonstrate chemosensitive disease and yields a median 5-yr survival of around 40-60% (3). Yet another group of patients who may benefit from ASCT are those with de novo high-risk International Prognostic Index (IPI) DLBCL, because survival rates remain unsatisfactorily low in these patients (7) . However, the role of upfront ASCT still has to be established in patients with newly diagnosed high-risk DLBCL (8, 9) . Improved selection of patients who may benefit from this intensive therapy regimen is desirable to avoid unnecessary side effects and costs.
outcome. Although several studies have been performed on this topic, the value of FDG-PET in this setting remains unclear due to differences in patient spectra, study methodology, and reported diagnostic estimates. Therefore, the value of pretransplant FDG-PET has not been defined yet by current guidelines (10, 11) . A systematic review and meta-analysis is required to gain more insight into the overall value of pretransplant FDG-PET and to identify potential directions for future research. The aim of this study was therefore to systematically review and meta-analyze the value of pretransplant FDG-PET in predicting outcome after ASCT in aggressive non-Hodgkin lymphoma.
Materials and methods

Search strategy
A MEDLINE search was conducted for original articles on the prognostic value of pretransplant FDG-PET in patients with aggressive non-Hodgkin lymphoma, from start date to May 16, 2016 . The applied search terms are displayed in Table 1 . Reference lists of included studies were explored for suitable articles that were not included by the initial MEDLINE search.
Study selection
Prospective or retrospective studies that reported data on the value of pretransplant FDG-PET in patients with aggressive non-Hodgkin lymphoma treated with ASCT in predicting treatment failure [i.e., either progressive, residual, or relapsed disease or end of progression-free survival (PFS)] or death [i.e., death rate or end of overall survival (OS)] were included. Both studies that used upfront ASCT for newly diagnosed aggressive non-Hodgkin lymphoma or transformed indolent lymphoma and studies that used ASCT as second-line therapy in patients with refractory/relapsed aggressive lymphoma were eligible for inclusion. Studies without original patient data, studies including <10 patients with aggressive non-Hodgkin lymphoma, studies that reported the same patient data in a larger study, studies that did not allow for separate data extraction of aggressive non-Hodgkin lymphoma patients from patients with other lymphoma subgroups (i.e., indolent or intermediate-grade non-Hodgkin lymphoma and Hodgkin lymphoma), studies that only applied a quantitative instead of a visual FDG-PET analysis, studies that mixed FDG-PET results with Gallium scan results, studies in which the treatment strategy was adapted on the basis of the pretransplant FDG-PET result (patients with evident chemo-insensitive disease exempted, because they usually not qualify for HDT and ASCT), studies in which patients were treated with allogeneic SCT instead of ASCT, and studies that did not report sufficient data about patients' prognosis according to pretransplant FDG-PET status were excluded.
Study quality
Studies were methodologically appraised using the Quality In Prognosis Studies (QUIPS) tool that was developed by Hayden et al. (12) . Risk of bias was evaluated in the following domains: (i) study participation, (ii) study attrition, (iii) prognostic factor measurement, (iv) outcome measurement, (v) study confounding, and (vi) statistical analysis and reporting (12) . Level of bias was scored as low, moderate, or high for these six domains in each individual study.
Meta-analysis
Studies that provided sufficient data to construct a 2 9 2 contingency table (with four cells for number of true-positives, false-positives, false-negatives, and true-negatives) could be used to calculate sensitivity and specificity of pretransplant FDG-PET in predicting treatment failure and/or death during follow-up. These studies were then meta-analyzed for all aggressive lymphomas together (whether newly diagnosed aggressive, transformed indolent, or refractory/relapsed aggressive non-Hodgkin lymphoma). First, the presence and influence of different threshold effects on sensitivity and specificity values across studies were assessed using Spearman q analysis. Spearman q is the correlation coefficient between the logit of the sensitivity and logit of 1 À specificity; values larger than 0.6 were considered to indicate the presence of a threshold effect. Second, interstudy heterogeneity beyond a potential threshold effect was assessed by calculating the diagnostic odds ratio (13) of each study and subjecting them to the Higgins and Thompson test, with heterogeneity defined as a I 2 exceeding 50% (14) . Pooled sensitivity and specificity were calculated if there was no threshold effect, and pooling was performed using either a fixed effects model (in case of interstudy heterogeneity) or a random effects model (in case of no interstudy heterogeneity). Further meta-analytical subgroup analyses were performed in case of interstudy heterogeneity. Predefined subgroup analyses were newly diagnosed aggressive lymphoma, transformed indolent lymphoma, and refractory/ relapsed aggressive non-Hodgkin lymphoma. P-values <0.05 Data on the prognostic value of pretransplant FDG-PET in predicting outcome at univariable and/or multivariable analysis in all aggressive lymphomas (whether newly diagnosed aggressive, transformed indolent, or refractory/relapsed aggressive non-Hodgkin lymphoma) were extracted from included studies and summarized.
Results
Literature search
The MEDLINE search revealed 4460 articles (Table 1) . After screening titles and abstracts, 35 articles remained. Of these, 13 were excluded because of non-separability of aggressive non-Hodgkin lymphoma patients from those with indolent or intermediate non-Hodgkin lymphoma or Hodgkin lymphoma, four were excluded because these studies did not report sufficient data about patients' prognosis according to pretransplant FDG-PET status, three were excluded because <10 patients with aggressive non-Hodgkin lymphoma were enrolled, two were excluded because they only enrolled patients with indolent non-Hodgkin lymphoma, one was excluded because it reported the same patients in another larger study, one was excluded because it only performed quantitative and no visual FDG-PET analysis, and one was excluded because of non-separability of FDG-PET scan results from Gallium scan results. Thus, 10 studies remained, of which one reported the results of DLBCL and transformed indolent lymphoma separately (16) . For analytical purposes, the latter was regarded as two different studies. Tables 2 and 3 show the details of the 11 included studies, which comprised a total of 664 aggressive non-Hodgkin lymphoma patients who underwent pretransplant FDG-PET.
Methodological quality Table 4 shows the level of bias for the six different QUIPS domains. In general, included studies were of poor methodological quality. There was moderate risk of bias in the domain of study participation in seven studies, because six studies (16) (17) (18) (19) (20) did not report whether refractory/relapsed disease was histologically verified and one study (21) reported that histological verification of relapsed disease was not performed in all cases. There was moderate risk of bias in the domain of prognostic factor measurement in seven studies, because five studies (16) (17) (18) 22) did not report which PET system (stand-alone PET or integrated PET/CT) was used, and two studies (20, 23) used a stand-alone PET system instead of an integrated PET/CT system. There was high risk of bias in the domain of outcome measurement in 10 studies (16) (17) (18) (19) (20) (21) (22) (23) (24) , because these studies did not report whether relapse after ASCT was histologically verified.
There was high risk of bias in the domain of study confounding in 11 studies due to several reasons. First, three studies (18, 19, 21) (16) did not report at all which induction therapy was used. Sixth, six studies (16, 19, 20, 24, 26) pooled patients who received various conditioning therapies in their survival analyses. Finally, one study (21) did not report at all which conditioning regimen was used. Table 5 displays the results of the 11 included studies. Seven studies (17, 18, 20, (22) (23) (24) 26) reported sufficient data for the calculation of sensitivity and specificity of pretransplant FDG-PET in predicting treatment failure after ASCT in all aggressive lymphomas (whether newly diagnosed aggressive, transformed indolent, or refractory/relapsed aggressive non-Hodgkin lymphoma), which ranged Four studies (18, 20, 22, 26) reported sufficient data for the calculation of sensitivity and specificity of pretransplant FDG-PET in predicting death after ASCT in all aggressive lymphomas (whether newly diagnosed aggressive, transformed indolent, or refractory/relapsed aggressive non-Hodgkin lymphoma), which ranged between 8.3% and 87.5% and between 65.6% and 72.0%, respectively. There was no threshold effect (Spearman q = 0.000, P = 1.000), but there was interstudy heterogeneity (I 2 = 68.1%). Pooled sensitivity and specificity (random effects) of pretransplant FDG-PET in predicting death were 54.5% (95% CI: 38.8-69.6%) and 68.7% (95% CI: 60.5-76.1%).
Meta-analysis
Subgroup analyses
Two studies (22, 24) reported sufficient data for the calculation of sensitivity and specificity of pretransplant FDG-PET in predicting treatment failure after ASCT in patients with newly diagnosed aggressive non-Hodgkin lymphoma, which ranged between 10.0% and 26.7% and between 62.5% and 73.2%, respectively. Threshold analysis (i.e., calculation of the Spearman q) was not possible due to the inclusion of only two studies, but there was no interstudy heterogeneity (I 2 = 40.4%). Pooled sensitivity and specificity of pretransplant FDG-PET in predicting treatment failure in newly diagnosed aggressive non-Hodgkin lymphoma were 20.0% (95% CI: 6.8-40.7%) and 70.0% (95% CI: 58.7-79.7%). Calculation of summary estimates of pretransplant FDG-PET in predicting death in patients with newly diagnosed aggressive non-Hodgkin lymphoma was not possible, because only one study (22) reported sufficient data for this analysis. This study reported a sensitivity of 8.3% and a specificity of 30.5% for pretransplant FDG-PET in predicting death in patients with newly diagnosed aggressive non-Hodgkin lymphoma (22) .
Three studies (17, 20, 26) reported sufficient data for the calculation of sensitivity and specificity of pretransplant FDG-PET in predicting treatment failure after ASCT in patients with refractory/relapsed aggressive non-Hodgkin lymphoma, which ranged between 58.8% and 73.3% and between 68.4% and 75.0%, respectively. There was no threshold effect (Spearman q = À1.000, P = 0.000) and no interstudy heterogeneity (I 2 = 0.0%). Pooled sensitivity and specificity of pretransplant FDG-PET in predicting treatment failure in refractory/relapsed aggressive non-Hodgkin lymphoma were 68.1% (95% CI: 52.9-80.9%) and 72.1% (95% CI: 61.4-81.2%). Two studies (20, 26) reported sufficient data for the calculation of sensitivity and specificity of pretransplant FDG-PET in predicting death after ASCT in patients with refractory/relapsed aggressive non-Hodgkin lymphoma, which ranged between 71.4% and 87.5% and between 67.7% and 72.0%, respectively. Threshold analysis (calculation of the Spearman q) was not possible due to the inclusion of only two studies, but there was no interstudy heterogeneity (I 2 = 0.0%). Pooled sensitivity and specificity of pretransplant FDG-PET in predicting death in refractory/relapsed aggressive non-Hodgkin lymphoma were 77.3% (95% CI: 54.6-92.2%) and 69.6% (95% CI: 55.9-81.2%).
Subgroup analysis in transformed indolent lymphoma was not performed, due to a lack of studies reporting sufficient data for the calculation of sensitivity and specificity in this subgroup.
Univariable and multivariable prognostic analyses in all aggressive lymphomas At univariable analysis, six studies (16, 17, 20, 21, 23, 26) reported pretransplant FDG-PET-positive patients to have a significantly higher risk (P < 0.05) of treatment failure, whereas five studies (16, 18, 19, 22, 24) reported no significant difference between pretransplant FDG-PET-positive and FDG-PET-negative patients. At multivariable analysis, five studies (16, 17, 21, 23, 26) reported pretransplant FDG-PET to have independent prognostic value in addition to the IPI in predicting treatment failure, whereas three studies (16, 18, 22) reported pretransplant FDG-PET to have no independent prognostic value.
At univariable analysis, six studies (16, 17, 20, 21, 23, 26) reported pretransplant FDG-PET-positive patients to have a significantly higher risk (P < 0.05) of experiencing death during follow-up, whereas five studies (16, 18, 19, 22, 24) reported no significant difference between pretransplant FDG-PET-positive and FDG-PET-negative patients. At multivariable analysis, five studies (16, 17, 21, 23, 26) reported pretransplant FDG-PET to have independent prognostic value in addition to the IPI in predicting death, whereas three studies (16, 18, 22) reported pretransplant FDG-PET to have no independent prognostic value.
Discussion
This systematic review and meta-analysis included 11 studies comprising a total of 664 patients with aggressive nonHodgkin lymphoma who underwent FDG-PET before ASCT. Overall, methodological quality of studies included was poor, with concerns in the domains of study participation (non-reporting of histological confirmation of refractory or relapsed disease), prognostic factor measurement (use of inferior stand-alone PET systems or non-reporting of the PET system that was used for image acquisition), and outcome measurement (lack of histological confirmation of refractory or relapsed disease after ASCT). Reappearance of FDG-avid foci on follow-up FDG-PET examinations after therapy has been shown to be insufficient proof of disease relapse, because a large proportion of these cases appear to be false-positive (27, 28) . Furthermore, there was high risk of bias in the domain of study confounding for all studies. This was due to the fact that included studies mixed patients with newly diagnosed aggressive non-Hodgkin lymphoma, refractory/relapsed aggressive non-Hodgkin lymphoma, and transformed indolent lymphoma treated with various induction and conditioning regimens in their survival analyses. Overall, there is a lack of studies that included a homogeneous group of aggressive non-Hodgkin lymphomas patients treated with homogeneous induction and consolidation regimens. Based on a meta-analysis of seven included studies, pooled sensitivity and specificity of pretransplant FDG-PET in all aggressive non-Hodgkin lymphomas were 54.0% and 73.1%. Based on a meta-analysis of four included studies, pooled sensitivity and specificity of pretransplant FDG-PET in all aggressive non-Hodgkin lymphomas were 54.5% and 68.7% in predicting death. However, there was interstudy heterogeneity, which disappeared in a subgroup analysis that solely included patients with newly diagnosed aggressive non-Hodgkin lymphoma and in another subgroup analysis that solely included patients with refractory/relapsed aggressive non-Hodgkin lymphoma. In the former group, pretransplant FDG-PET performed poorly, and in the latter group, pretransplant FDG-PET performed only moderately in predicting outcome after ASCT.
The unsatisfactorily low value of pretransplant FDG-PET in identifying patients who will experience a poor outcome after ASCT can be explained by multiple reasons. First, it has been convincingly proven that FDG-PET performed at baseline has suboptimal sensitivity for the detection of lymphomatous involvement of the bone marrow (29) . Consequently, pretransplant FDG-PET cannot evaluate for the presence of residual bone marrow lesions after salvage chemotherapy. Second, detection of lymphomatous cells is hampered by the limited spatial resolution of PET, which is currently on the order of 6-7 mm. As a result, small amounts of residual lymphoma cells cannot be detected (30, 31) . The fact that patients with negative postchemotherapy FDG-PET scans have a decreased risk of disease relapse when treated with additional radiation therapy supports this hypothesis (32) (33) (34) (35) . Moreover, even patients with incurable, baseline FDG-avid indolent non-Hodgkin lymphomas or palliative patients with aggressive non-Hodgkin lymphomas who receive a non-curative treatment may achieve a negative FDG-PET status. Therefore, a negative FDG-PET result cannot rule out residual lymphomatous cells and cannot confirm cure. False-positive FDG-PET results after induction treatment, on the other hand, are also a major concern, as demonstrated by several studies (36, 37) .
A study by Hamlin et al. (38) published in 2003 introduced the secondary IPI, a derivative of the standard IPI (39), for prognostication in patients with refractory/relapsed DLBCL treated with ASCT. For this purpose, 150 patients treated with ifosfamide, carboplatin, and etoposide followed by HDT and ASCT with or without total body irradiation were included. IPI risk factors that were of significant prognostic value at multivariable analysis were LDH more than upper limit of normal, presence of stage III or IV disease, and Karnofsky performance status <80%. However, standard IPI risk factors age older than 60 yr and more than one site of extranodal involvement were not predictive and, consequently, not included in the prognostic model for the development of the secondary IPI. Patients with 0 (n = 20), 1 (n = 40), and 2-3 (n = 90) risk factors had 4-yr PFS of 70%, 39%, and 16%, and a 4-yr OS of 74%, 49%, and 18%, respectively. However, a drawback is that the secondary IPI was developed in the prerituximab era and it has not been validated in patients treated with rituximab-containing regimens. Future studies in refractory/relapsed aggressive DLBCL should compare pretransplant FDG-PET with the secondary IPI.
The present systematic review and meta-analysis had several limitations. First, methodological quality of studies included was poor, as a result of which the reported diagnostic value of pretransplant FDG-PET may have been seriously biased. Second, although studies applying pretransplant FDG-PET-directed therapy were excluded, some studies excluded a few patients from their analysis because of evident chemo-insensitivity, and these studies were not excluded. However, patients with insensitivity to induction treatment usually do not qualify for HDT with ASCT; therefore, exclusion of these patients reflects clinical practice. Third, only seven studies reported sufficient data for meta-analyzing the value of pretransplant FDG-PET in predicting treatment failure, and only four studies reported sufficient data for meta-analyzing the value of pretransplant FDG-PET in predicting death after ASCT. Fourth, minimum follow-up time was <24 months in nine of 11 studies. Considering the fact that the majority of disease relapses occur within the first 3 yr after ASCT (4), disease relapse rate and diagnostic value of pretransplant FDG-PET would be different when a longer follow-up time would have been applied.
In conclusion, at present, pretransplant FDG-PET cannot be recommended for predicting outcome in aggressive nonHodgkin lymphoma after ASCT, because the available literature suffers from major methodological flaws, and reported estimates of diagnostic performance are unsatisfactorily low (i.e., poor in newly diagnosed and moderate in refractory/relapsed aggressive non-Hodgkin lymphoma).
Funding
This work was financially supported by an Alpe d'HuZes/ Dutch Cancer Society Bas Mulder Award for T.C.K. (grant number 5409). Data collection, data analysis and interpretation of data, writing of the manuscript, and decision to submit were left to the authors' discretion and were not influenced by Alpe d'HuZes/Dutch Cancer Society.
Potential conflict of interest
None (all authors).
